La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Integer Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Integer Holdings..

Integer Holdings (NYSE:ITGR) Azioni, Catena delle Opzioni

Integer Holdings

Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into two business segments based on the product type: medical and nonmedical. The medical segment uses the firm's technologies to produce components and finished medical devices, and it generates the vast majority of revenue. The company earns more than half of its revenue in the United States.

Integer Holdings Corporation Common Stock

Integer Holdings Corp

Integral

Redburn Atlantic analyst Bingqing Zhu initiates coverage on Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Buy rating and announces Price Target of $82.

News

Price Target

Initiation

Analyst Ratings

MDLZ

Redburn Atlantic Initiates Coverage On Mondelez International with Buy Rating, Announces Price Target of $82

IBKR

Interactive Brokers Files Form 8-K/A Disclosing Revised Operating Results For Q3

EF Hutton analyst Jason Kolbert maintains Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and maintains $17 price target.

IMUX

EF Hutton Maintains Buy on Immunic, Maintains $17 Price Target

WIIM

LOGI

Logitech International shares are trading lower. The company reported Q2 financial results.

At a cost of&nbsp;$267 million, the plant is the largest and most important component of the&nbsp;Navajo-Gallup Water Supply Project. When completed, the project will provide water supplies to approximately 250,000 people in 43 Navajo chapters.
Jacobs will design and build the San Juan Lateral Water Treatment Plant to initially treat up to 18.8 million gallons of water per day, with the ability to double the plant&#39;s capacity.

Contracts

Jacobs Says It Is Selected By US Bureau Of Reclamation To Design And Build San Juan Lateral Water Treatment Plant In Northwest New Mexico

Genuine Parts shares are trading lower after the company reported mixed Q3 financial results and cut its FY24 EPS below estimates.

Redburn Atlantic analyst Bingqing Zhu initiates coverage on Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Sell rating and announces Price Target of $165.

Redburn Atlantic Initiates Coverage On Hershey with Sell Rating, Announces Price Target of $165

DASH

Fiserv Enters Collaboration With DoorDash To Embed Financial Services Within Digital Platform

Earnings

Earnings Misses

SIFY

Sify Technologies Q2 Sales $122.673M Miss $152.700M Estimate

Canaccord Genuity analyst Carey Macrury downgrades Gatos Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATO#NYSE">GATO</a>) from Buy to Hold.

Downgrades

GATO

Canaccord Genuity Downgrades Gatos Silver to Hold

GE Aerospace shares are trading lower. The company reported Q3 financial results.

GPRK

GeoPark Receives Approval From The Argentinian Securities Regulator To Issue Up To $500M In Debt Securities Over Next Five Years

Keybanc analyst Sophie Karp downgrades Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) from Overweight to Sector Weight.

Keybanc Downgrades Duke Energy to Sector Weight

Deutsche Bank analyst Koosh Patel maintains AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) with a Buy and raises the price target from $110 to $115.

Deutsche Bank Maintains Buy on AerCap Holdings, Raises Price Target to $115

LXEO

Lexeo Therapeutics Says Interim Data From Ongoing Phase 1/2 Trial Of LX1001 Have Been Selected As Late-breaking Oral Presentation At CTAD Conference

Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.70 by 7.65 percent. This is a 5.17 percent increase over earnings of $1.74 per share from the same period last year. The company reported quarterly sales of $4.952 billion which missed the analyst consensus estimate of $5.048 billion by 1.89 percent. This is a 3.51 percent decrease over sales of $5.132 billion the same period last year.

Earnings Beats

CORRECTION: Kimberly-Clark Q3 2024 Adj. EPS $1.83 Beats $1.70 Estimate, Sales $4.952B Miss $5.048B Estimate

Keybanc analyst Jackson Ader initiates coverage on Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Overweight rating and announces Price Target of $40.

ZETA

Keybanc Initiates Coverage On Zeta Global Holdings with Overweight Rating, Announces Price Target of $40

Deutsche Bank analyst Hillary Cacanando maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Buy and raises the price target from $125 to $160.

FTAI

Deutsche Bank Maintains Buy on FTAI Aviation, Raises Price Target to $160

Biogen presentations include a late breaking oral presentation highlighting the conclusive data from the Phase 2 IGNAZ study of felzartamab for IgA nephropathy (IgAN).&nbsp;

BIIB

Biogen Plans To Present Variety Of New Data From Its Felzartamab Clinical Development Program At Kidney Week 2024

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 3</a>0, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Organon &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</h3>
<ul>
<li>Organon will release its third quarter 2024 financial results on Oct. 31. The company's stock fell around 12% over the past month and has a <a href="https://www.benzinga.com/quote/OGN">52-week low of $10.84</a>.</li>
<li>RSI Value: 28.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>OGN Price Action: Shares of Organon fell 0.9% to close at $17.45 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">latest OGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="907" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197.png" alt="" class="wp-image-607146" style="width:757px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197-768x710.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></figure>
<h3 class="wp-block-heading">Arcutis Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>)&nbsp;</h3>
<ul>
<li>On Oct. 21, Arcutis Canada announced Health Canada approval of ZORYVE&#xAE; Foam to treat seborrheic dermatitis in individuals 9 years of age and older. Dr. Melinda Gooderham, medical director at the SKiN Centre for Dermatology and a principal Canadian investigator in the pivotal Phase 3 STRATUM trial said, &#8220;The approval of ZORYVE foam by Health Canada is a significant development in the management of this condition. Clinical trial data show close to 80% of patients achieving treatment success at week 8 and rapid itch relief in as little as 48 hours.&#8221; The company's stock fell around 14% over the past five days and has a 52-week low of $1.76.</li>
<li>RSI Value: 28.13</li>
<li>ARQT Price Action: Shares of Arcutis Biotherapeutics fell 4.7% to close at $8.31 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">trend in ARQT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192.png" alt="" class="wp-image-606848" style="width:703px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192-768x704.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">TransMedics Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>)</h3>
<ul>
<li>TransMedics Group will release financial results for the third quarter after market close on Monday, Oct. 28. The company's shares fell around 22% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/MGRX">low of $36.42</a>.</li>
<li>RSI Value: 29.60</li>
<li>TMDX Price Action: Shares of TransMedics fell 1.7% to close at $124.48 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">breakout in TMDX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="818" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193.png" alt="" class="wp-image-606851" style="width:702px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193-768x696.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41429862/this-analyst-with-85-accuracy-rate-sees-around-11-upside-in-netflix-here-are-5-stock-picks-for-last">This Analyst With 85% Accuracy Rate Sees Around 11% Upside In Netflix &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

ARQT

TMDX

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Integer Holdings (ITGR – Research Report), with a price ...

Benchmark Co. Sticks to Their Buy Rating for Integer Holdings (ITGR)

23 high-quality cheap small-caps with positive revisions - BofA

Invesco Small Cap Growth Fund Q2 2024 Review

Baron Discovery Fund Q2 2024 Shareholder Letter

Franklin Small Cap Growth Fund Q2 2024 Commentary

Small cap stocks that could perform best during 'downturns' – BofA

In a report released today, Craig Bijou from Bank of America Securities maintained a Buy rating on Integer Holdings (ITGR – Research Report). The c...

Bank of America Securities Keeps Their Buy Rating on Integer Holdings (ITGR)

Benchmark Co. analyst Robert Wasserman maintained a Buy rating on Integer Holdings (ITGR – Research Report) today and set a price target of $130.00...

Integer Holdings: More Than Re-Rated Here

Benchmark analyst Robert Wasserman raised the firm's price target on Integer (ITGR) to $140 from $130 and keeps a Buy rating on the shares ahead of...

Integer price target raised to $140 from $130 at Benchmark

ACHC

ACLS

ADMA

ADUS

AEIS

ALAB

ALGM

ALRM

ARHS

ATMU

AXNX

BASE

BCAP

BLFS

BRBR

BROE

BWXT

CAKE

CDNA

COCO

CRCQW

CRDO

CYTK

ESNT

ESTA

EWCZ

EXAS

EXLS

EYPT

FRPT

FRSH

FTAIM

FTAIN

FTAIO

FTAIP

GKOS

GLOB

GTLB

GWRE

INDI

INSM

INSP

ITGR

ITRI

KNSL

LBRT

LSCC

MANH

MNDY

NMIH

NTRA

NVMI

ONON

ONTO

PAGS

PCOR

RGEN

RMBS

SILK

SITE

SITM

SMAR

STNE

STVN

TMXXF

TWST

VCEL

VCYT

WING

Press Releases

Integer Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024

Financing

Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028 and Upsize of Revolving Credit Facility

Integer Holdings Corporation Reports Second Quarter 2024 Results

Integer Holdings Releases Inaugural Impact Report

Integer to Present at the 2024 Wells Fargo Healthcare Conference

General

Integer Completes Two Irish Facility Expansions to Support Growth, Strengthen Capabilities in Critical Medtech Region

Integer Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024

Integer Holdings Corporation to Divest Non-Medical Business for $50 million

Ultralife Corporation to Acquire Electrochem Solutions, Inc.

Health Care

Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028

Comments

Integer Holdings

Integer Holdings (ITGR) Opzioni

Integer Holdings (NYSE:ITGR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO